Cargando…
MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series
BACKGROUND: Cancer treatment-induced bone loss (CTIBL) is the most common adverse event experienced by patients affected by breast cancer (BC) patients, without bone metastases. Bone modifying agents (BMAs) therapy is prescribed for the prevention of CTIBL, but it exposes patients to the risk of MRO...
Autores principales: | Mauceri, Rodolfo, Coppini, Martina, Attanasio, Massimo, Bedogni, Alberto, Bettini, Giordana, Fusco, Vittorio, Giudice, Amerigo, Graziani, Filippo, Marcianò, Antonia, Nisi, Marco, Isola, Gaetano, Leonardi, Rosalia Maria, Oteri, Giacomo, Toro, Corrado, Campisi, Giuseppina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899375/ https://www.ncbi.nlm.nih.gov/pubmed/36739399 http://dx.doi.org/10.1186/s12903-023-02732-6 |
Ejemplares similares
-
Oral Surgical Management of Bone and Soft Tissues in MRONJ Treatment: A Decisional Tree
por: Marcianò, Antonia, et al.
Publicado: (2020) -
CD34 and CD105 Microvessels in Resected Bone Specimen May Implicate Wound Healing in MRONJ
por: Marcianò, Antonia, et al.
Publicado: (2021) -
A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis
por: Campisi, Giuseppina, et al.
Publicado: (2021) -
Medication-Related Osteonecrosis of Jaws (MRONJ) Prevention and Diagnosis: Italian Consensus Update 2020
por: Campisi, Giuseppina, et al.
Publicado: (2020) -
One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost–benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ)
por: Fusco, Vittorio, et al.
Publicado: (2022)